These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 9522319)

  • 1. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
    Lübbert H; Nauert C
    Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
    Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
    Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables.
    Gräser T; Rössner P; Schubert K; Müller A; Bönisch U; Oettel M
    Maturitas; 1997 Dec; 28(2):169-79. PubMed ID: 9522325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.
    Koninckx PR; Spielmann D
    Gynecol Endocrinol; 2005 Aug; 21(2):82-9. PubMed ID: 16294460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.
    Boerrigter PJ; van de Weijer PH; Baak JP; Fox H; Haspels AA; Kenemans P
    Maturitas; 1996 May; 24(1-2):63-71. PubMed ID: 8794436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
    Samsioe G; Boschitsch E; Concin H; De Geyter C; Ehrenborg A; Heikkinen J; Hobson R; Arguinzoniz M; Ibarra de Palacios P; Scheurer C; Schmidt G;
    Climacteric; 2006 Oct; 9(5):368-79. PubMed ID: 17080587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
    Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
    Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
    Lahdenperä S; Puolakka J; Pyörälä T; Luotola H; Taskinen MR
    Atherosclerosis; 1996 May; 122(2):153-62. PubMed ID: 8769679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
    Saure A; Planellas J; Poulsen HK; Jaszczak P
    Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period.
    Pornel B; Spielmann D
    Gynecol Endocrinol; 2005 Aug; 21(2):74-81. PubMed ID: 16294458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
    Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations.
    Mattsson LA; Bohnet HG; Gredmark T; Torhorst J; Hornig F; Hüls G
    Obstet Gynecol; 1999 Jul; 94(1):61-5. PubMed ID: 10389719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen.
    Rees MC; Kuhl H; Engelstein M; Mattila L; Mäenpää J; Mustonen M;
    Climacteric; 2004 Mar; 7(1):23-32. PubMed ID: 15259280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate.
    Gambacciani M; Spielmann D; Genazzani AR
    Gynecol Endocrinol; 2005 Aug; 21(2):65-73. PubMed ID: 16294457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.